within Pharmacolibrary.Drugs.ATC.A;

model A02BA53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.42,
    Cl             = 400 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.0011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Famotidine is a histamine H2-receptor antagonist used to reduce stomach acid production. It is indicated for the treatment of peptic ulcers, gastroesophageal reflux disease (GERD), and conditions of pathological hypersecretory states such as Zollinger-Ellison syndrome. Famotidine, both alone and in combination with antacids or other components (ATC code A02BA53), is approved for use today to control gastric acid-related disorders.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects administered famotidine in fixed-dose combinations, as there are no directly referenced PK studies for ATC code A02BA53. Parameters are based on extrapolation from monotherapy data.</p><h4>References</h4><ol><li><p>Deeks, ED (2013). Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. <i>Clinical drug investigation</i> 33(9) 689–697. DOI:<a href=&quot;https://doi.org/10.1007/s40261-013-0113-x&quot;>10.1007/s40261-013-0113-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23881568/&quot;>https://pubmed.ncbi.nlm.nih.gov/23881568</a></p></li><li><p>Singh, R, et al., &amp; Palaparthy, R (2025). Effect of Food Intake or Coadministration With an Acid-Reducing Agent on Lenacapavir Pharmacokinetics Following Oral Administration. <i>Clinical pharmacology in drug development</i> 14(4) 324–332. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1513&quot;>10.1002/cpdd.1513</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39844693/&quot;>https://pubmed.ncbi.nlm.nih.gov/39844693</a></p></li><li><p>Xi, E, et al., &amp; Zhu, G (2024). Residue-Free Orally Administered Drug Carrier Based on a Porous Aromatic Framework for Efficient Multisite Treatment. <i>Small (Weinheim an der Bergstrasse, Germany)</i> 20(45) e2404643–None. DOI:<a href=&quot;https://doi.org/10.1002/smll.202404643&quot;>10.1002/smll.202404643</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39016121/&quot;>https://pubmed.ncbi.nlm.nih.gov/39016121</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A02BA53;
